These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 7734374)

  • 21. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis.
    Zöller B; Dahlbäck B
    Lancet; 1994 Jun; 343(8912):1536-8. PubMed ID: 7911873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of the FV:Q506 mutation in unselected oncology patients.
    Otterson GA; Monahan BP; Harold N; Steinberg SM; Frame JN; Kaye FJ
    Am J Med; 1996 Oct; 101(4):406-12. PubMed ID: 8873512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance to activated protein C caused by a factor V gene mutation.
    Zöller B; Dahlbäck B
    Curr Opin Hematol; 1995 Sep; 2(5):358-64. PubMed ID: 9372020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
    Dahlbäck B
    Thromb Haemost; 1995 Jul; 74(1):139-48. PubMed ID: 8578447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population].
    Ehrenforth S; Klinke S; von Depka Prondzinski M; Kreuz W; Ganser A; Scharrer I
    Dtsch Med Wochenschr; 1999 Jun; 124(25-26):783-7. PubMed ID: 10414227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factor V:Q506 mutation and anticardiolipin antibodies in systemic lupus erythematosus.
    Bengtsson A; Zöller B; de Frutos PG; Dahlbäck B; Sturfelt G
    Lupus; 1996 Dec; 5(6):598-601. PubMed ID: 9116703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of activated protein C resistance using a new and rapid venom-based test: STA Staclot APC-R.
    Oger E; Leroyer C; Mercier B; Van Dreden P; Bressollette L; De Saint-Martin L; Le Moigne E; Blouch MT; Thuillier N; Amiral J; Ferec C; Abgrall JF; Mottier D
    Blood Coagul Fibrinolysis; 1998 Jun; 9(4):355-9. PubMed ID: 9690807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Point mutation G-->A nucleotide 1691 factor V gene as a cause of developing thrombotic complications in a family with plasma resistance to activated protein C].
    Lew Andowski KL; Rozek M; Turowiecka Z; Markiewicz WT; Zawilska K
    Pol Arch Med Wewn; 1996 May; 95(5):464-70. PubMed ID: 8848415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries.
    Holm J; Zöller B; Berntorp E; Erhardt L; Dahlbäck B
    J Intern Med; 1996 Mar; 239(3):221-6. PubMed ID: 8772620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance.
    Melichart M; Kyrle PA; Eichinger S; Rintelen C; Mannhalter C; Pabinger I
    Wien Klin Wochenschr; 1996; 108(19):607-10. PubMed ID: 8921576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis.
    Svensson PJ; Zöller B; Mattiasson I; Dahlbäck B
    J Intern Med; 1997 May; 241(5):379-85. PubMed ID: 9183305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Activated C protein resistance: laboratory study and prevalence of the defect in the Chilean population].
    Pereira J; Quiroga T; Goycoolea M; Muñoz B; Hidalgo P; Kaltwasser G; Mezzano D
    Rev Med Chil; 1996 Jun; 124(6):663-8. PubMed ID: 9041721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism.
    Dahlbäck B
    J Intern Med; 1995 Mar; 237(3):221-7. PubMed ID: 7891043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular genetics of venous thromboembolism.
    Dahlbäck B
    Ann Med; 1995 Apr; 27(2):187-92. PubMed ID: 7632412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection.
    Ekberg H; Svensson PJ; Simanaitis M; Dahlbäck B
    Transplantation; 2000 Apr; 69(8):1577-81. PubMed ID: 10836365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low risk of venous thrombosis in two families with combined type I plasminogen deficiency and factor V R506Q mutation.
    Castaman G; Ruggeri M; Tosetto A; Rodeghiero F
    Am J Hematol; 1998 Apr; 57(4):344-7. PubMed ID: 9544982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to activated protein C and a novel factor V gene mutation.
    Voelkerding KV
    Clin Lab Med; 1996 Mar; 16(1):169-86. PubMed ID: 8867589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation.
    Simioni P; Scarano L; Gavasso S; Sardella C; Girolami B; Scudeller A; Girolami A
    Br J Haematol; 1996 Feb; 92(2):435-41. PubMed ID: 8603014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Familial thrombophilia and activated protein C resistance: thrombotic risk in pregnancy?
    Cook G; Walker ID; McCall F; Conkie JA; Greer IA
    Br J Haematol; 1994 Aug; 87(4):873-5. PubMed ID: 7986734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Arterial and venous thrombosis in two Italian families with the factor V Arg506-->Gln mutation.
    Montaruli B; Voorberg J; Tamponi G; Borchiellini A; Muleo G; Pannocchia A; van Mourik JA; Schinco P
    Eur J Haematol; 1996 Jul; 57(1):96-100. PubMed ID: 8698138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.